← Back to Screener
Insulet Corporation (PODD)
Price$200.87
Favorite Metrics
Price vs S&P 500 (26W)-43.97%
Price vs S&P 500 (4W)-19.78%
Market Capitalization$14.05B
P/E Ratio (Annual)56.87x
All Metrics
P/CF (Annual)24.69x
Book Value / Share (Quarterly)$21.53
P/TBV (Annual)14.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)27.54%
Cash Flow / Share (Quarterly)$4.97
Price vs S&P 500 (YTD)-32.46%
Gross Margin (TTM)71.63%
Net Profit Margin (TTM)9.13%
EPS (TTM)$3.48
10-Day Avg Trading Volume0.82M
EPS Excl Extra (TTM)$3.48
Revenue Growth (5Y)24.53%
EPS (Annual)$3.44
ROI (Annual)10.03%
Gross Margin (Annual)71.63%
Net Profit Margin (5Y Avg)8.67%
Cash / Share (Quarterly)$10.17
P/E Basic Excl Extra (TTM)56.85x
Revenue Growth QoQ (YoY)31.18%
EPS Growth (5Y)101.61%
P/E Normalized (Annual)56.87x
ROA (Last FY)7.75%
Revenue Growth TTM (YoY)30.73%
EBITD / Share (TTM)$6.15
ROE (5Y Avg)16.60%
Operating Margin (TTM)12.92%
Cash Flow / Share (Annual)$4.97
P/B Ratio9.27x
P/B Ratio (Quarterly)13.20x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.27x
Net Interest Coverage (TTM)33.64x
ROA (TTM)7.49%
EPS Growth QoQ (YoY)5.86%
EV / EBITDA (TTM)32.45x
EPS Incl Extra (Annual)$3.44
Current Ratio (Annual)2.81x
Quick Ratio (Quarterly)1.81x
3-Month Avg Trading Volume0.92M
52-Week Price Return-18.75%
EV / Free Cash Flow (Annual)40.84x
P/E Incl Extra (TTM)56.85x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$19.86
P/S Ratio (Annual)5.19x
Asset Turnover (Annual)0.85x
52-Week High$354.88
Operating Margin (5Y Avg)10.26%
EPS Excl Extra (Annual)$3.44
CapEx CAGR (5Y)5.67%
Tangible BV CAGR (5Y)19.45%
26-Week Price Return-35.23%
Quick Ratio (Annual)1.81x
13-Week Price Return-27.98%
Total Debt / Equity (Annual)0.63x
Current Ratio (Quarterly)2.81x
Enterprise Value$14,285.322
Revenue / Share Growth (5Y)22.38%
Asset Turnover (TTM)0.82x
Book Value / Share Growth (5Y)18.67%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.74x
Pretax Margin (Annual)12.54%
Cash / Share (Annual)$10.17
3-Month Return Std Dev31.41%
Gross Margin (5Y Avg)67.99%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)32.73%
EBITDA Interim CAGR (5Y)56.37%
ROE (Last FY)16.31%
Net Interest Coverage (Annual)10.98x
EPS Basic Excl Extra (Annual)$3.44
P/FCF (TTM)40.17x
Receivables Turnover (TTM)6.14x
EV / Free Cash Flow (TTM)40.84x
Total Debt / Equity (Quarterly)0.63x
EPS Incl Extra (TTM)$3.48
Receivables Turnover (Annual)6.14x
ROI (TTM)9.20%
P/S Ratio (TTM)5.19x
Pretax Margin (5Y Avg)8.46%
Revenue / Share (Annual)$37.67
Tangible BV / Share (Annual)$19.86
Forward P/E31.61x
Price vs S&P 500 (52W)-53.84%
P/E Ratio (TTM)56.85x
EPS Growth TTM (YoY)-38.62%
Year-to-Date Return-28.32%
5-Day Price Return2.99%
EPS Normalized (Annual)$3.44
ROA (5Y Avg)6.06%
Net Profit Margin (Annual)9.12%
Month-to-Date Return-2.91%
Cash Flow / Share (TTM)$2.67
EBITD / Share (Annual)$6.13
EPS Growth (3Y)273.82%
Operating Margin (Annual)12.92%
LT Debt / Equity (Annual)0.61x
P/CF (TTM)24.69x
ROI (5Y Avg)7.37%
P/E Excl Extra (TTM)56.85x
LT Debt / Equity (Quarterly)0.61x
EPS Basic Excl Extra (TTM)$3.48
P/TBV (Quarterly)14.30x
P/B Ratio (Annual)13.20x
Inventory Turnover (TTM)1.74x
Pretax Margin (TTM)12.54%
Book Value / Share (Annual)$21.53
Price vs S&P 500 (13W)-30.85%
Net Margin Growth (5Y)64.81%
Beta1.35x
P/FCF (Annual)40.17x
Revenue / Share (TTM)$38.32
ROE (TTM)17.37%
52-Week Low$194.61
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.24
4.26
4.26
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
GMEDGLOBUS MEDICAL INC | 4.37x | 30.08% | 67.41% | 20.33% | $96.82 |
About
Insulet manufactures the Omnipod system, a smartphone-controlled, disposable insulin infusion device that simplifies continuous insulin therapy for diabetic patients. FDA-approved since 2005, the system has been adopted by approximately 500,000 patients worldwide, establishing Insulet as a leader in automated insulin delivery solutions.